Merck Archives - World School of Life Sciences IP

Beyond Keytruda: Merck’s Oncology Pipeline Expansion Through M&A

Tanu Goyal July 22, 2024

Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022

Will Merck pay royalty charges to John Hopkins University over Keytruda® patents?

Tanu Goyal March 22, 2024

Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion

WSLI

Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.